Skip to main content
Erschienen in: Pathology & Oncology Research 1/2015

01.01.2015 | Research

Pathologic Assessment of Response to Chemotherapy in Colorectal Cancer Liver Metastases after Hepatic Resection: Which Method to Use?

verfasst von: K Dede, F Salamon, L Landherr, F Jakab, A Bursics

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with metastatic colorectal cancer receive chemotherapy prior liver resection more and more frequently. Histopathologic assessment methods of the resected specimen could evaluate the response to chemotherapy. In this study it is analyzed if these histopathologic changes are specific to preoperative chemotherapy and if these methods have correlation with survival.

Methods

Sixty three patients with available pathology slides, resected for colorectal cancer liver metastases were enrolled in this study. 46 patients (73 %) received neoadjuvant chemotherapy. Five pathological evaluation methods were compared according to the literature: [1] residual tumor cell ratio, [2] tumor regression grade (TRG) scoring system, [3] modified tumor regression grade (mTRG) scoring system with the type of necrosis, [4] pattern of tumor regression and [5] the tumor thickness at the tumor-normal interface (TNI).

Results

Analyzing the pathological methods between the chemotherapy (CTX) and the non-chemotherapy group (NC), we found that that four evaluation methods showed significant and one showed strong correlation with the use of chemotherapy. (Residual tumor cell ratio: p = 0.08; TRG: p <0.01; mTRG: p = 0.03; pattern of tumor regression: p <0.01; TNI: p = 0.02). In the chemotherapy group none of the analyzed pathological methods showed significant correlation with progression free survival (PFS) or with overall survival (OS). Residual tumor cell ratio, TRG and the pattern of tumor cells showed positive but not significant correlation with OS and PFS and a slight difference in the group of patients with TNI <2 mm could be documented.

Conclusions

Tumor regression grade (TRG) and tumor thickness at the tumor-normal interface (TNI) were the most useful methods for pathological response evaluation and these methods had some correlation with survival. According to these data, authors concluded, that a reproducible and well defined scoring system, based on different histopathological evaluation methods should be developed to predict more accurately the effect of neoadjuvant chemotherapy in CRCLM patients.
Literatur
1.
Zurück zum Zitat Nordlinger B, Vauthey J-N, Poston G et al (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9(4):212–218PubMedCrossRef Nordlinger B, Vauthey J-N, Poston G et al (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9(4):212–218PubMedCrossRef
2.
Zurück zum Zitat Chua T. C., Saxena A., Liauw A., et al.: Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases Ann Surg Oncol. 2010 (2):492–501., 17. Chua T. C., Saxena A., Liauw A., et al.: Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases Ann Surg Oncol. 2010 (2):492–501., 17.
3.
Zurück zum Zitat Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26(11):1830–1835PubMedCrossRef Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26(11):1830–1835PubMedCrossRef
4.
Zurück zum Zitat Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20(6):985–92PubMedCrossRef Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20(6):985–92PubMedCrossRef
5.
Zurück zum Zitat Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644–657PubMedCentralPubMedCrossRef Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644–657PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Dede K, Mersich T, Besznyák I et al (2013) Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assesment. Pathol Oncol Res 19:501–508 Dede K, Mersich T, Besznyák I et al (2013) Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assesment. Pathol Oncol Res 19:501–508
7.
Zurück zum Zitat Scoggins CR, Campbell ML, Landry CS et al (2009) Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 16(1):35–41PubMedCrossRef Scoggins CR, Campbell ML, Landry CS et al (2009) Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 16(1):35–41PubMedCrossRef
8.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment is solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment is solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef
9.
Zurück zum Zitat ChunYS, Vauthey JN, Boonsirikamchai P et al. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal LiverMetastases JAMA. 2 [Epub ahead of print].009 302 (21):2338–2344. ChunYS, Vauthey JN, Boonsirikamchai P et al. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal LiverMetastases JAMA. 2 [Epub ahead of print].009 302 (21):2338–2344.
10.
Zurück zum Zitat Dan G, Blazer III, Yoji K et al (2008) Pathologic response to preoperative chemotherapy: a New outcome End point after resection of hepatic colorectal metastases. J Clin Onc 25(33):5344–5351 Dan G, Blazer III, Yoji K et al (2008) Pathologic response to preoperative chemotherapy: a New outcome End point after resection of hepatic colorectal metastases. J Clin Onc 25(33):5344–5351
11.
Zurück zum Zitat Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304PubMedCrossRef Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304PubMedCrossRef
12.
Zurück zum Zitat Chang HHI, Leeper WR, Chan G et al (2012) Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 36:570–576PubMedCrossRef Chang HHI, Leeper WR, Chan G et al (2012) Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 36:570–576PubMedCrossRef
13.
Zurück zum Zitat Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110(12):2761–2767PubMedCrossRef Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110(12):2761–2767PubMedCrossRef
14.
Zurück zum Zitat Maru DM, Kopetz S, Boonsirikamchai P et al (2010) Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287–129 Maru DM, Kopetz S, Boonsirikamchai P et al (2010) Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287–129
15.
Zurück zum Zitat Gómez Dorronsoro ML, Vera R, Ortega L, et al. Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy Clin Transl Oncol. [Epub ahead of print]. Gómez Dorronsoro ML, Vera R, Ortega L, et al. Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy Clin Transl Oncol. [Epub ahead of print].
16.
Zurück zum Zitat Knijn N, de Ridder JA, Punt CJ et al (2013) Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 63(2):149–56PubMedCrossRef Knijn N, de Ridder JA, Punt CJ et al (2013) Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 63(2):149–56PubMedCrossRef
17.
Zurück zum Zitat Ng JKS, Urbanski SJ, Mangat N et al (2008) Colorectal liver metastases contract centripetally with a response to chemotherapy. Cancer 112:362–71 Ng JKS, Urbanski SJ, Mangat N et al (2008) Colorectal liver metastases contract centripetally with a response to chemotherapy. Cancer 112:362–71
18.
Zurück zum Zitat Dede K, Láng I, Pörneczi B et al (2013) Preoperative chemotherapy in the surgical treatment of colorectal liver metastases. Magy Seb 66(6):325–30PubMedCrossRef Dede K, Láng I, Pörneczi B et al (2013) Preoperative chemotherapy in the surgical treatment of colorectal liver metastases. Magy Seb 66(6):325–30PubMedCrossRef
19.
Zurück zum Zitat Shindoh J, Loyer EM, Kopetz S et al (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome End point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572PubMedCentralPubMedCrossRef Shindoh J, Loyer EM, Kopetz S et al (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome End point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Egger ME, Cannon RM, Metzger TL et al (2013) Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 216:845–56PubMedCrossRef Egger ME, Cannon RM, Metzger TL et al (2013) Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 216:845–56PubMedCrossRef
21.
Zurück zum Zitat Poultsides GA, Bao F, Servais EL et al (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis. Predicts outcome. Ann Surg Oncol 19:2797–2804PubMedCrossRef Poultsides GA, Bao F, Servais EL et al (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis. Predicts outcome. Ann Surg Oncol 19:2797–2804PubMedCrossRef
22.
Zurück zum Zitat Gruenberger T, Arnold D, Rubbia-Brandt L (2012) Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol 21:309–15PubMedCrossRef Gruenberger T, Arnold D, Rubbia-Brandt L (2012) Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol 21:309–15PubMedCrossRef
23.
Zurück zum Zitat Loupakis F, Schirripa M, CaparelloC et al.: Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab Br J Cancer. 2013. [Epub ahead of print]. Loupakis F, Schirripa M, CaparelloC et al.: Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab Br J Cancer. 2013. [Epub ahead of print].
24.
Zurück zum Zitat Klinger M, Tamandl D, Eipeldauer S et al (2010) Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17(8):2059–65PubMedCrossRef Klinger M, Tamandl D, Eipeldauer S et al (2010) Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17(8):2059–65PubMedCrossRef
Metadaten
Titel
Pathologic Assessment of Response to Chemotherapy in Colorectal Cancer Liver Metastases after Hepatic Resection: Which Method to Use?
verfasst von
K Dede
F Salamon
L Landherr
F Jakab
A Bursics
Publikationsdatum
01.01.2015
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2015
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9803-9

Weitere Artikel der Ausgabe 1/2015

Pathology & Oncology Research 1/2015 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.